Lung Cancer Market Research Report - Global Forecast to 2023

Lung Cancer Market Research Report - Global Forecast to 2023

ID: MRFR/HC/0679-CRR | May, 2017 | Region: Global | 102 pages | Cooked Research Reports

Global Lung Cancer Market Information, by Type (SCLC, NSCLC); by treatment (Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT), Laser therapy); by end users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast to 2023



Market Synopsis of Global Lung Cancer Market:


Market Scenario:


Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the cancers with NSCLC representing the remaining. The cure rates for the two types of lung cancers are different and the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage IV.


The global market of Lung Cancer is expected to reach USD 36929.8 million in 2023 from USD 15219.7 million in 2016 with a CAGR of 13.5% during the forecast period 2017-2023.



Global Lung Cancer Market, by Types, 2016 (%):


 


Intended Audience



  • Lung Cancer Drug Manufacturers

  • Cancer research facilities

  • Market Research and Consulting Service Providers

  • Hospitals & Research Laboratories



Key Players for Global Lung Cancer Market:

Some of the key players in this market are: F. Hoffmann-La Roche AG, Novartis, PFIZER INC, Merck & Co., Inc., BRISTOL-MYERS SQUIBB, ELI Lilly and Company, Sanofi and others.



Segments:


Global Lung Cancer Market has been segmented on the basis of types which comprises of SCLC and NSCLC. On the basis of treatments it is segmented into Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy. On the basis of end users, it includes Hospitals & Clinics, Cancer Research Centers and Laboratories.



Regional Analysis of Global Lung Cancer Market:


The global market for Lung Cancer is growing steadily. The global lung cancer market on the basis of region comprises of North America, Europe, Asia Pacific and Middle East & Africa. The global market for Lung Cancer is growing with the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most common type of lung cancer globally. The global Lung Cancer market reached USD 36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured the second largest market globally and is expected to reach USD 8,536.3 million by 2023 due to the growing demand and need for lung cancer drugs, and the growing prevalence of lung cancer.

The report for Global Lung Cancer Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

2.1 Research Objective

2.2 Assumptions & Limitations

2.2.1 Assumptions

2.2.2 Limitations

2.3 Market Structure

3.1 Primary Research

3.2 Secondary Research

4.1 Introduction

4.2 Bargaining Power of Buyer

4.3 Bargaining power of suppliers

4.3.1 Threat from substitute

4.3.2 Threat from a New Entrant

4.3.3 Intensity of Competitive Rivalry

5.1 Drivers

5.1.1 Smoking

5.1.2 Environmental pollution

5.1.3 Rising cases of infections

5.1.4 Growing rates of early detection and awareness

5.1.5 Rising rates of fast growing lung cancer

5.1.6 Reimbursements and growing health insurance

5.2 Restraints

5.2.1 Poor efficacy, cure rates and side effects of present treatment

5.2.2 High failure rates of lung transplant surgeries

5.2.3 High malignant nature and faster growth of lung cancer

5.2.4 Poor life expectancy and quality of life of patients undergoing lung cancer treatment

5.2.5 Loss of patents of lung cancer drugs

5.2.6 Scarcity of lung organ and long waiting lines

5.3 Opportunities

5.3.1 Rising research and development

5.3.2 Huge market

5.3.3 Rising support from public and philanthropic bodies and increasing collaboration will help to drive down development cost

5.3.4 Targeted and genetic therapies

5.4 Challenges

5.4.1 High bar for any new treatment

5.4.2 The scarcity of lung transplant organs

6.1 SCLC Lung Cancer

6.2 NSCLC Lung Cancer

7.1 Surgery

7.2 Chemotherapy

7.3 Radiotherapy

7.4 Photodynamic therapy (PDT)

7.5 Laser therapy

8.1 Hospital & Clinics

8.2 Cancer Research Centers

8.3 Laboratories

9.1 North America

9.1.1 US 41

9.1.2 Canada

9.2 Europe

9.3 Germany

9.3.1 France

9.3.2 Italy

9.3.3 UK

9.3.4 Spain

9.3.5 Rest of Europe

9.4 Asia Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Republic of Korea

9.4.5 Australia

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 UAE

9.5.2 Saudi Arabia

9.5.3 Egypt

9.5.4 Rest of Middle East & Africa

11.1 F. Hoffmann-La Roche AG

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Novartis

11.2.1 Overview

11.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

11.2.3 FINANCIAL UPDATES

11.2.4 KEY DEVELOPMENTS

11.3 PFIZER INC.

11.3.1 Overview

11.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

11.3.3 FINANCIAL UPDATES

11.3.4 KEY DEVELOPMENTS

11.4 Merck & Co., Inc.

11.4.1 Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Developments

11.5 BRISTOL-MYERS SQUIBB

11.5.1 Overview

11.5.2 Product Portfolio

11.5.3 Financial Overview

11.5.4 KEY DEVELOPMENTS

11.6 ELI Lilly and Company

11.6.1 Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 KEY DEVELOPMENTS

11.7 Sanof

11.7.1 Company Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Overview

11.7.4 Key Development

11.7.5 SWOT Analysis

TABLE 1 LUNG CANCER DRUGS, PIPELINE 2016
TABLE 2 GLOBAL LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 3 GLOBAL SCLC MARKET US$ MILLION (2014 & 2023)
TABLE 4 GLOBAL NSCLC MARKET US$ MILLION (2014 & 2023)
TABLE 5 GLOBAL LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 6 GLOBAL SURGERY MARKET US$ MILLION (2014-2023)
TABLE 7 GLOBAL CHEMOTHERAPY MARKET US$ MILLION (2014-2023)
TABLE 8 GLOBAL RADIOTHERAPY MARKET US$ MILLION (2014-2023)
TABLE 9 GLOBAL PHOTODYNAMIC THERAPY (PDT) MARKET US$ MILLION (2014-2023)
TABLE 10 GLOBAL LASER THERAPY MARKET US$ MILLION (2014-2023)
TABLE 11 GLOBAL LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 12 GLOBAL HOSPITAL & CLINICS MARKET US$ MILLION (2014-2023)
TABLE 13 GLOBAL CANCER RESEARCH CENTERS MARKET US$ MILLION (2014-2023)
TABLE 14 GLOBAL LABORATORIES MARKET US$ MILLION (2014-2023)
TABLE 15 GLOBAL LUNG CANCER MARKET BY REGIONS US$ MILLION (2014-2023)
TABLE 16 NORTH AMERICA LUNG CANCER MARKET BY COUNTRY US$ MILLION (2014-2023)
TABLE 17 NORTH AMERICA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 18 NORTH AMERICA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 19 NORTH AMERICA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 20 US LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 21 US LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 22 US LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 23 CANADA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 24 CANADA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 25 CANADA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 26 EUROPE LUNG CANCER MARKET BY COUNTRY US$ MILLION (2014-2023)
TABLE 27 EUROPE LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 28 EUROPE LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 29 EUROPE LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 30 GERMANY LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 31 GERMANY LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 32 GERMANY LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 33 FRANCE LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 34 FRANCE LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 35 FRANCE LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 36 ITALY LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 37 ITALY LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 38 ITALY LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 39 UK LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 40 UK LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 41 UK LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 42 SPAIN LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 43 SPAIN LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 44 SPAIN LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 45 REST OF EUROPE LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 46 REST OF EUROPE LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 47 REST OF EUROPE LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 48 ASIA PACIFIC LUNG CANCER MARKET BY COUNTRY US$ MILLION (2014-2023)
TABLE 49 ASIA PACIFIC LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 50 ASIA PACIFIC LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 51 ASIA PACIFIC LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 52 CHINA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 53 CHINA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 54 CHINA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 55 JAPAN LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 56 JAPAN LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 57 JAPAN LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 58 INDIA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 59 INDIA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 60 INDIA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 61 REPUBLIC OF KOREA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 62 REPUBLIC OF KOREA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 63 REPUBLIC OF KOREA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 64 AUSTRALIA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 65 AUSTRALIA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 66 AUSTRALIA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 67 REST OF ASIA PACIFIC LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 68 REST OF ASIA PACIFIC LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 69 REST OF ASIA PACIFIC LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 70 MIDDLE EAST & AFRICA LUNG CANCER MARKET BY COUNTRY US$ MILLION (2014-2023)
TABLE 71 MIDDLE EAST & AFRICA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 72 MIDDLE EAST & AFRICA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 73 MIDDLE EAST & AFRICA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 74 UAE LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 75 UAE LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 76 UAE LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 77 SAUDI ARABIA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 78 SAUDI ARABIA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 79 SAUDI ARABIA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 80 EGYPT LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 81 EGYPT LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 82 EGYPT LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 83 REST OF MIDDLE EAST & AFRICA LUNG CANCER MARKET BY TYPES US$ MILLION (2014-2023)
TABLE 84 REST OF MIDDLE EAST & AFRICA LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2014-2023)
TABLE 85 REST OF MIDDLE EAST & AFRICA LUNG CANCER MARKET BY END USERS US$ MILLION (2014-2023)
TABLE 86 MERCK & CO.: PRODUCT OVERVIEW
TABLE 87 MERCK & CO.: KEY DEVELOPMENTS
TABLE 88 PIPELINES BY MERCK & CO., INC.
TABLE 89 SANOFI: KEY DEVELOPMENT

FIGURE 1 GLOBAL LUNG CANCER MARKET BY TYPES MARKET SHARE 2016 (%)
FIGURE 2 GLOBAL LUNG CANCER MARKET BY TREATMENTS MARKET SHARE 2016 (%)
FIGURE 3 GLOBAL LUNG CANCER MARKET BY END USERS MARKET SHARE 2016 (%)
FIGURE 4 GLOBAL LUNG CANCER MARKET BY REGION 2016 MARKET SHARE (%)
FIGURE 5 RESEARCH PROCESS
FIGURE 6 GLOBAL LUNG CANCER MARKET BY TYPES US$ MILLION (2014 & 2023)
FIGURE 7 GLOBAL LUNG CANCER MARKET BY TREATMENTS US$ MILLION (2016 & 2023)
FIGURE 8 GLOBAL LUNG CANCER MARKET BY END USERS US$ MILLION (2014 & 2023)
FIGURE 9 GLOBAL LUNG CANCER MARKET BY REGIONS US$ MILLION (2014 & 2023)
FIGURE 10 NORTH AMERICA LUNG CANCER MARKET BY COUNTRY MARKET SHARE 2016 (%)
FIGURE 11 EUROPE LUNG CANCER MARKET BY COUNTRY MARKET SHARE 2016 (%)
FIGURE 12 ASIA PACIFIC LUNG CANCER MARKET BY COUNTRY MARKET SHARE 2016 (%)
FIGURE 13 MIDDLE EAST & AFRICA LUNG CANCER MARKET BY COUNTRY MARKET SHARE 2016 (%)
FIGURE 14 GLOBAL LUNG CANCER MARKET; COMPETITIVE LANDSCAPE
FIGURE 15 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE
FIGURE 16 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE
FIGURE 17 NOVARTIS FINANCIAL DATA: REVENUE AND R&D
FIGURE 18 NOVARTIS FINANCIAL DATA: SEGMENTAL REVENUE
FIGURE 19 NOVARTIS FINANCIAL DATA: GEOGRAPHICAL REVENUE
FIGURE 20 PFIZER FINANCIAL DATA: REVENUE AND R&D
FIGURE 21 PFIZER FINANCIAL DATA SEGMENTAL REVENUE
FIGURE 22 PFIZER FINANCIAL DATA GEOGRAPHICAL REVENUE
FIGURE 23 MERCK FINANCIAL DATA: REVENUE
FIGURE 24 MERCK SEGMENTAL REVENUE
FIGURE 25 MERCK GEOGRAPHICAL REVENUE
FIGURE 26 BRISTOL-MYERS SQUIBB REVENUE
FIGURE 27 BRISTOL-MYERS SQUIBB SEGMENTAL REVENUE
FIGURE 28 BRISTOL-MYERS SQUIBB GEOGRAPHICAL REVENUE
FIGURE 29 ELI LILLY AND COMPANY REVENUE
FIGURE 30 ELI LILLY AND COMPANY SEGMENTAL REVENUE
FIGURE 31 ELI LILLY AND COMPANY GEOGRAPHICAL REVENUE
FIGURE 32 SANOFI: RECENT FINANCIAL
FIGURE 33 SANOFI: BUSINESS REVENUE MIX (2015)
FIGURE 34 SANOFI: GEOGRAPHIC REVENUE MIX
FIGURE 35 SANOFI: SWOT ANALYSIS